MedTrace Logo

Investigating the Role of Biomarkers in Predicting Outcome for COVID 19

NCT04363008 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-11-29

No results posted yet for this study

Summary

Emergent experimental and anecdotal evidence has indicated that critically ill COVID-19 patients demonstrate two patient sub-types (called phenotypes). In one group the disease progresses slowly and patients have a low potential of developing mild respiratory failure, but in the other group, an exaggerated immune response (hyper-inflammation/cytokine storm) may be linked to the onset of precipitous respiratory failure, termed acute respiratory distress syndrome. This syndrome is responsible for a large portion of COVID-19 associated mortality. Thus, determining links between hyper-inflammation and acute respiratory distress syndrome in COVID-19 patients is of immediate importance. Blood samples will undergo a number of analyses to help us to understand as much as possible about COVID-19. We will also study any differences in physiologic and cytokine levels before and after patients are treated with immunomodulatory therapies as part of clinical care in COVID-19 patients.

Conditions

  • COVID 19

Interventions

DIAGNOSTIC_TEST

serum inflammatory biomarkers

Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Mypinder Sekhon, MD · University of British Columbia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2022-09-30
Completion
2024-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04363008 on ClinicalTrials.gov